Rabbit Recombinant Monoclonal PSMD14 antibody. Carrier free. Suitable for WB, IP and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ICC/IF | Flow Cyt | WB | IHC-P | IP | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Not recommended | Tested |
Mouse | Not recommended | Not recommended | Predicted | Not recommended | Predicted |
Rat | Not recommended | Not recommended | Predicted | Not recommended | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. The PSMD14 subunit is a metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains within the complex. Plays a role in response to double-strand breaks (DSBs): acts as a regulator of non-homologous end joining (NHEJ) by cleaving 'Lys-63'-linked polyubiquitin, thereby promoting retention of JMJD2A/KDM4A on chromatin and restricting TP53BP1 accumulation. Also involved in homologous recombination repair by promoting RAD51 loading.
POH1, PSMD14, 26S proteasome non-ATPase regulatory subunit 14, 26S proteasome regulatory subunit RPN11, 26S proteasome-associated PAD1 homolog 1
Rabbit Recombinant Monoclonal PSMD14 antibody. Carrier free. Suitable for WB, IP and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab247774 is the carrier-free version of Anti-PSMD14 antibody [EPR4258] ab109130.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
PSMD14 also known as POH1 or RPN11 is a proteasome subunit involved in the regulation of protein degradation. This protein has a molecular mass of approximately 34 kDa and forms an essential part of the 19S regulatory particle of the proteasome complex. PSMD14 is expressed in various tissues but shows significant expression levels in the brain heart and skeletal muscles. By deubiquitinating substrates PSMD14 contributes to the recycling of ubiquitin for further use in the cell’s ubiquitin-proteasome pathway.
PSMD14 functions as a vital component of the 19S proteasome which is integrated into the proteolytic 26S proteasome complex. The protein's deubiquitinating activity plays a role in maintaining proteostasis by removing ubiquitin chains from substrates destined for degradation. This process is important for regulating protein quality control cell cycle progression and response to oxidative stress among other cellular processes. As part of the proteasome complex PSMD14’s activity impacts cellular homeostasis and contributes to cellular responses to various stimuli.
PSMD14 is instrumental in the ubiquitin-proteasome system which is essential for targeted protein degradation modulation of the cell cycle and regulation of transcription factors. It interacts with other proteasome components like PSMD12 and PSMD3 to form a functional proteasome unit. This protein is significant in the NF-kB signaling pathway where it influences the degradation of inhibitor proteins allowing for the activation of NF-kB a critical transcription factor in immune response and cell survival.
PSMD14’s function connects it to cancer and neurodegenerative conditions. Deregulation or mutations in PSMD14 have been implicated in various cancers possibly through disturbed protein degradation which leads to aberrant cell cycle progression and survival. It also relates to neurodegenerative diseases like Alzheimer's as impaired proteasome function can lead to the accumulation of misfolded proteins. PSMD14 interacts with proteins like UCH37 which is also linked to the pathogenesis of these diseases highlighting the significance of controlled proteolysis in maintaining cellular health.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-PSMD14 antibody [EPR4258] ab109130, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-PSMD14 antibody [EPR4258] (Anti-PSMD14 antibody [EPR4258] ab109130) at 1/1000 dilution
Lane 1: HepG2 cell lysate at 10 µg
Lane 2: A431 cell lysate at 10 µg
Lane 3: K562 cell lysate at 10 µg
Lane 4: Namalwa cell lysate at 10 µg
Lane 5: HeLa cell lysate at 10 µg
Lane 6: MCF7 cell lysate at 10 µg
Predicted band size: 35 kDa
This data was developed using Anti-PSMD14 antibody [EPR4258] ab109130, the same antibody clone in a different buffer formulation.PSMD14 was immunoprecipitated from 0.35 mg K-562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysate 10 µg with Anti-PSMD14 antibody [EPR4258] ab109130 at 1/50 dilution (2µg). VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: K-562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysate 10 µg
Lane 2: abab109130 IP in K-562 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-PSMD14 antibody [EPR4258] ab109130 in K-562 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
All lanes: Immunoprecipitation - Anti-PSMD14 antibody [EPR4258] (Anti-PSMD14 antibody [EPR4258] ab109130)
Predicted band size: 35 kDa
Observed band size: 35 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com